Sex Disparities in Oncology Clinical Trials: Moving Beyond Counting Women Toward True Equity
核心洞察
A growing body of research highlights persistent sex-based disparities in oncology clinical trial enrollment, with women often underrepresented relative to disease burden.
Sex differences in adverse event risk are documented, with female patients experiencing higher rates of severe toxicities from immunotherapy (搜索), targeted therapy (搜索), and chemotherapy (搜索).
Biological factors including sex hormone signaling, cytochrome P450 (搜索) enzyme variation, and dimorphic immune responses may underlie differential treatment outcomes and toxicities.
Sex-based disparities in oncology clinical trial enrollment and outcomes are drawing renewed scrutiny from researchers, who argue that simply increasing the number of women in trials is insufficient—what is needed is a fundamental shift toward equity-focused trial design and analysis.
A comprehensive body of evidence published across multiple Nature journals and the Journal of Clinical Oncology underscores that women remain underrepresented in certain oncology trials relative to the disease burden in the population, and that biological sex influences both treatment efficacy and toxicity in ways that are not yet fully understood or accounted for in clinical practice.
The Enrollment Gap: Representation Versus Disease Burden
Research by Benjamin and Rezazadeh, presented at the 2025 ASCO Genitourinary Cancers Symposium, characterized genitourinary drug approvals by the FDA from 2020 to 2024, revealing patterns in trial participation that do not always align with real-world disease prevalence. A related analysis by Miyagi and colleagues found gender disparities in both clinical trial participation and real-world utilization of systemic therapy for urothelial carcinoma (搜索), suggesting that the gap between trial cohorts and treated populations extends beyond enrollment to actual clinical care.
Krischak et al. directly examined whether women are underrepresented in urologic oncology clinical trials, concluding that significant disparities persist. These findings echo concerns raised as early as 1998 by Merkatz, who documented the historical exclusion of women from clinical research and the resulting gaps in evidence for female patients.
Sex Differences in Treatment Outcomes and Toxicity
The consequences of underrepresentation extend beyond equity metrics. Kammula and colleagues, publishing in Nature Communications, analyzed outcome differences by sex across oncology clinical trials and identified meaningful variations in treatment responses between male and female patients. Their work suggests that pooling data across sexes may obscure clinically relevant differences.
Unger et al. conducted a landmark analysis of sex differences in severe adverse event risk among patients receiving immunotherapy (搜索), targeted therapy (搜索), or chemotherapy (搜索) in cancer clinical trials, published in the Journal of Clinical Oncology. Their findings documented that female patients experience higher rates of severe adverse events across multiple treatment modalities—a pattern that has significant implications for dosing, monitoring, and supportive care strategies.
Biological Mechanisms Underlying Sex Differences
Several biological mechanisms may explain these disparities. Hoffmann and colleagues, writing in Immunity, detailed how sex hormone signaling regulates immune function, providing a mechanistic framework for understanding differential responses to immunotherapy (搜索). Canzian et al. further explored sex-related differences in immunotherapy toxicities, describing dimorphic responses that may be driven by hormonal and genetic factors.
Pharmacokinetic differences also play a role. Zanger and Schwab's work on cytochrome P450 (搜索) enzymes in drug metabolism, published in Pharmacology & Therapeutics, established that genetic variation and gene expression regulation of these enzymes differ by sex, potentially affecting drug exposure and toxicity profiles for many oncology agents.
Beyond Inclusion: The Call for Equity
Tannenbaum and colleagues, in a widely cited Nature paper, argued that sex and gender analysis improves science and engineering broadly, calling for systematic integration of these variables into study design rather than treating them as post-hoc considerations.
Taylor et al. highlighted another dimension of the problem: disparities in physician evaluation and intervention for sexual health toxicity in cancer survivors, suggesting that even when toxicities occur, they may be addressed differently based on patient gender.
Barriers to enrollment identified by Kumar and colleagues include healthcare provider perspectives that may inadvertently limit trial access for certain populations. Meanwhile, Benjamin and Kalebasty noted that the genitourinary medical oncology workforce composition itself may influence trial enrollment patterns and patient access.
The FDA's Drug Trials Snapshots Program has provided transparency into clinical trial participation patterns, enabling researchers to evaluate progress and identify areas requiring further improvement. However, experts including Dr. Arash Rezazadeh Kalebasty, Dr. Sheetal Desai, and Dr. Maheswari Senthil of the University of California, Irvine, emphasize that counting women is only the first step—true equity requires understanding and addressing the biological, social, and structural factors that shape differential outcomes.